Dunn · The Journal of clinical endocrinology and metabolism 1980 · in vitro competitive binding assay · n=?

Testosterone-estradiol binding globulin binds to 2-methoxyestradiol with greater affinity than to testosterone.

Cited 56 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

In vitro bench/binding study with no human clinical data

PubMed 7190578 · doi:10.1210/jcem-51-2-404 · record verified 2026-08-29

What was done

The authors measured the relative binding affinity of 2-methoxyestradiol, testosterone, and 17 beta-estradiol to testosterone-estradiol binding globulin (TeBG) using competitive displacement of [3H]-testosterone on a solid-phase Con A-Sepharose matrix. They also evaluated 2-methoxyestradiol binding to the androgen receptor via competitive displacement of [3H]-dihydrotestosterone in 64-24 rat mammary tumor cells.

What was found

The relative binding activities for TeBG were 2.0 for 2-methoxyestradiol, 1.0 for testosterone, and 0.32 for 17 beta-estradiol. 2-Methoxyestradiol showed only low-affinity binding to the androgen receptor, paralleling its established low affinity for estrogen receptors.

Why it matters

This identified 2-methoxyestradiol as the first known endogenous steroid that binds with higher affinity to TeBG (SHBG) than testosterone while exhibiting minimal affinity for classical androgen and estrogen receptors.

Limits

The abstract describes exclusively in vitro competitive binding assays and does not report sample sizes, replicate numbers, or assay variability metrics. In vivo physiological consequences, plasma protein distribution, and metabolic clearance were not evaluated.

Cited by